Regulation of b2-Adrenergic Receptor Function by Conformationally Selective Single-Domain Intrabodies s

Molecular Pharmacology

Volumn 85, Issue 3, 2014, Pages 472-481

  Staus, Dean P ^a   Wingler, Laura M ^a   Strachan, Ryan T ^a   Rasmussen, Soren G F ^b   Pardon, Els ^c   Ahn, Seungkirl ^a   Steyaert, Jan ^c   Kobilka, Brian K ^d   Lefkowitz, Robert J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; NANOBODY;

AMINO ACID SEQUENCE; ARTICLE; CELL LINE; CELL STRAIN HEK293; HUMAN; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN BINDING; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; CELL LINE; CYCLIC AMP; G-PROTEIN-COUPLED RECEPTOR KINASES; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, G-PROTEIN-COUPLED; SEQUENCE ALIGNMENT; SINGLE-DOMAIN ANTIBODIES;

EID: 84894049358     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.089516     Document Type: Article

References (41)

1. Barlow JN, Conrath K, and Steyaert J (2009) Substrate-dependent modulation of enzyme activity by allosteric effector antibodies. BiochimBiophys Acta 1794:1259-1268.
2. Barnea G, Strapps W, Herrada G, Berman Y, Ong J, Kloss B, Axel R, and Lee KJ (2008) The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci USA 105:64-69.
3. Benovic JL, Kühn H, Weyand I, Codina J, Caron MG, and Lefkowitz RJ (1987) Functional desensitization of the isolated beta-adrenergic receptor by the betaadrenergic receptor kinase: Potential role of an analog of the retinal protein arrestin (48-kDa protein). Proc Natl Acad Sci USA 84:8879-8882.
4. Bertin B, Freissmuth M, Jockers R, Strosberg AD, and Marullo S (1994) Cellular signaling by an agonist-activated receptor/Gs alpha fusion protein. Proc Natl Acad Sci USA 91:8827-8831.
5. Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, Forsayeth JR, Guettier JM, Chang WC, Pei Y, and McCarthy KD et al. (2008) Engineering GPCR signaling pathways with RASSLs. Nat Methods 5:673-678.
6. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
7. Daaka Y, Luttrell LM, and Lefkowitz RJ (1997) Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88-91.
8. DeLean A and Lefkowitz RJ (1980) Dihydroergocryptine binding and alphaadrenoreceptors in smooth muscle. Nature 283:109-110.
9. Fan F, Binkowski BF, Butler BL, Stecha PF, Lewis MK, and Wood KV (2008) Novel genetically encoded biosensors using firefly luciferase. ACS Chem Biol 3:346-351.
10. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276:24433-24436.
11. Gupta A, Heimann AS, Gomes I, and Devi LA (2008) Antibodies against G-protein coupled receptors: Novel uses in screening and drug development. Comb Chem High Throughput Screen 11:463-467.
12. Gurevich VV, Pals-Rylaarsdam R, Benovic JL, Hosey MM, and Onorato JJ (1997) Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem 272:28849-28852.
13. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, Rasmussen SG, Sunahara RK, El-Samad H, and Huang B et al. (2013) Conformational biosensors reveal GPCR signalling from endosomes. Nature 495:534-538.
14. Kahsai AW, Xiao K, Rajagopal S, Ahn S, Shukla AK, Sun J, Oas TG, and Lefkowitz RJ (2011) Multiple ligand-specific conformations of the b2-adrenergic receptor. Nat Chem Biol 7:692-700.
15. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hübner H, Pardon E, Valant C, and Sexton PM et al. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101-106.
16. Lagerström MC and Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339-357.
17. Lo AS, Zhu Q, and Marasco WA (2008) Intracellular antibodies (intrabodies) and their therapeutic potential. Handbook Exp Pharmacol (181):343-373.
18. Milletti F (2012) Cell-penetrating peptides: Classes, origin, and current landscape. Drug Discov Today 17:850-860.
19. Muyldermans S (2013) Nanobodies: Natural single-domain antibodies. Annu Rev Biochem 82:775-797.
20. Neves SR, Ram PT, and Iyengar R (2002) G protein pathways. Science 296: 1636-1639.
21. Nobles M, Benians A, and Tinker A (2005) Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. Proc Natl Acad Sci USA 102: 18706-18711.
22. Oyen D, Srinivasan V, Steyaert J, and Barlow JN (2011) Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. J Mol Biol 407: 138-148.
23. Qin K, Dong C, Wu G, and Lambert NA (2011) Inactive-state preassembly of G(q)-coupled receptors and G(q) heterotrimers. Nat Chem Biol 7:740-747.
24. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM, Violin JD, and Lefkowitz RJ (2011) Quantifying ligand bias at seventransmembrane receptors. Mol Pharmacol 80:367-377.
25. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, and Kobilka TS et al. (2011a) Structure of a nanobodystabilized active state of the b(2) adrenoceptor. Nature 469:175-180.
26. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, and Calinski D et al. (2011b) Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477:549-555.
27. Reiter E, Ahn S, Shukla AK, and Lefkowitz RJ (2012) Molecular mechanism of b-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52:179-197.
28. Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, and Conrath K (2004) Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem 279:51965-51972.
29. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, and Lefkowitz RJ (2006) beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281:1261-1273.
30. Shenoy SK and Lefkowitz RJ (2011) b-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32:521-533.
31. Shukla AK, Xiao K, and Lefkowitz RJ (2011) Emerging paradigms of b-arrestindependent seven transmembrane receptor signaling. Trends Biochem Sci 36: 457-469.
32. Steyaert J and Kobilka BK (2011) Nanobody stabilization of G protein-coupled receptor conformational states. Curr Opin Struct Biol 21:567-572.
33. Toll L, Pajak K, Plazinska A, Jozwiak K, Jimenez L, Kozocas JA, Tanga MJ, Bupp JE, and Wainer IW (2012) Thermodynamics and docking of agonists to the b(2)-adrenoceptor determined using [(3)H](R,R')-4-methoxyfenoterol as the marker ligand. Mol Pharmacol 81:846-854.
34. Tremblay J.M., Kuo C.L., Abeijon C., Sepulveda J., Oyler G., Hu X., Jin M.M., and Shoemaker C.B. (2010). Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 56:990-998.
35. Vincke C and Muyldermans S (2012) Introduction to heavy chain antibodies and derived Nanobodies. Methods Mol Biol 911:15-26.
36. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, and Lark MW (2010) Selectively engaging b-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335:572-579.
37. Wang CI and Lewis RJ (2013) Emerging opportunities for allosteric modulation of G-protein coupled receptors. Biochem Pharmacol 85:153-162.
38. Wang L, Martin B, Brenneman R, Luttrell LM, and Maudsley S (2009) Allosteric modulators of g protein-coupled receptors: Future therapeutics for complex physiological disorders. J Pharmacol Exp Ther 331:340-348.
39. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787.
40. Williams LT and Lefkowitz RJ (1977) Molecular pharmacology of alpha adrenergic receptors: Utilization of [3H]dihydroergocryptine binding in the study of pharmacological receptor alterations. Mol Pharmacol 13:304-313.
41. Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, and Kobilka B (2006) Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol 2:417-422.